Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | HTR2A | P28223 | 5/20 | 0.35 |
| ▸ | DRD3 | P35462 | 5/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769264 | 0.85 | CHRM2 (0.39) | CHRM2MCHR1DRD2HRH3 | |
| SCHEMBL768708 | 0.85 | CHRM2 (0.39) | CHRM2MCHR1HRH3 | |
| SCHEMBL768889 | 0.84 | CHRM2 (0.39) | CHRM2MCHR1HRH3 | |
| SCHEMBL768948 | 0.84 | MCHR1 (0.43) | CHRM2MCHR1ACHE | |
| SCHEMBL767545 | 0.84 | CHRM2 (0.39) | CHRM2MCHR1HRH3 | |
| SCHEMBL768103 | 0.83 | HRH3 (0.41) | CHRM2DRD2HRH3 | |
| SCHEMBL15061368 | 0.83 | CHRM2 (0.58) | CHRM2 | |
| SCHEMBL769143 | 0.82 | CHRM2 (0.40) | CHRM2MCHR1DRD2HTR2ADRD3 | |
| SCHEMBL768358 | 0.81 | HDAC6 (0.38) | CHRM2MCHR1HRH3 | |
| SCHEMBL768439 | 0.81 | CHRM2 (0.39) | CHRM2MCHR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | CHRM2 2/4885MCHR1 239/4885ACHE 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.